Protective	protective	O	O
effect	effect	O	O
of	of	O	O
a	a	O	O
specific	specific	O	O
platelet-activating	platelet-activating	O	O
factor	factor	O	O
antagonist	antagonist	O	O
,	,	O	O
BN	bn	O	O
52021	52021	O	O
,	,	O	O
on	on	O	O
bupivacaine-induced	bupivacaine-induced	O	O
cardiovascular	cardiovascular	O	O
impairments	impairments	O	O
in	in	O	O
rats	rats	O	O
.	.	O	O

Administration	administration	O	O
of	of	O	O
the	the	O	O
local	local	O	O
anaesthetic	anaesthetic	O	O
bupivacaine	bupivacaine	S_chemical	O
(	(	O	O
1.5	1.5	O	O
or	or	O	O
2	2	O	O
mg/kg	mg/kg	O	O
,	,	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
to	to	O	O
rats	rats	O	O
elicited	elicited	O	O
a	a	O	O
marked	marked	O	O
decrease	decrease	O	O
of	of	O	O
mean	mean	O	O
arterial	arterial	O	O
blood	blood	O	O
pressure	pressure	O	O
(	(	O	O
MBP	mbp	O	O
)	)	O	O
and	and	O	O
heart	heart	O	O
rate	rate	O	O
(	(	O	O
HR	hr	O	O
)	)	O	O
leading	leading	O	O
to	to	O	O
death	death	O	S_disease
(	(	O	O
in	in	O	O
67	67	O	O
%	%	O	O
or	or	O	O
90	90	O	O
%	%	O	O
of	of	O	O
animals	animals	O	O
respectively	respectively	O	O
)	)	O	O
.	.	O	O

Intravenous	intravenous	O	O
injection	injection	O	O
of	of	O	O
the	the	O	O
specific	specific	O	O
platelet-activating	platelet-activating	O	O
factor	factor	O	O
(	(	O	O
PAF	paf	O	O
)	)	O	O
antagonist	antagonist	O	O
BN	bn	O	O
52021	52021	O	O
(	(	O	O
10	10	O	O
mg/kg	mg/kg	O	O
)	)	O	O
,	,	O	O
30	30	O	O
min	min	O	O
before	before	O	O
bupivacaine	bupivacaine	S_chemical	O
administration	administration	O	O
(	(	O	O
2	2	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
suppressed	suppressed	O	O
both	both	O	O
the	the	O	O
decrease	decrease	O	O
of	of	O	O
MBP	mbp	O	O
and	and	O	O
HR	hr	O	O
.	.	O	O

In	in	O	O
contrast	contrast	O	O
,	,	O	O
doses	doses	O	O
of	of	O	O
1	1	O	O
mg/kg	mg/kg	O	O
BN	bn	O	O
52021	52021	O	O
given	given	O	O
30	30	O	O
min	min	O	O
before	before	O	O
or	or	O	O
10	10	O	O
mg/kg	mg/kg	O	O
administered	administered	O	O
5	5	O	O
min	min	O	O
before	before	O	O
i.v	i.v	O	O
.	.	O	O

injection	injection	O	O
of	of	O	O
bupivacaine	bupivacaine	S_chemical	O
were	were	O	O
ineffective	ineffective	O	O
.	.	O	O

When	when	O	O
BN	bn	O	O
52021	52021	O	O
(	(	O	O
20	20	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
was	was	O	O
injected	injected	O	O
immediately	immediately	O	O
after	after	O	O
bupivacaine	bupivacaine	S_chemical	O
(	(	O	O
2	2	O	O
mg/kg	mg/kg	O	O
)	)	O	O
,	,	O	O
a	a	O	O
partial	partial	O	O
reversion	reversion	O	O
of	of	O	O
the	the	O	O
decrease	decrease	O	O
of	of	O	O
MBP	mbp	O	O
and	and	O	O
HR	hr	O	O
was	was	O	O
observed	observed	O	O
,	,	O	O
whereas	whereas	O	O
the	the	O	O
dose	dose	O	O
of	of	O	O
10	10	O	O
mg/kg	mg/kg	O	O
was	was	O	O
ineffective	ineffective	O	O
.	.	O	O

A	a	O	O
partial	partial	O	O
recovery	recovery	O	O
of	of	O	O
bupivacaine-induced	bupivacaine-induced	O	O
ECG	ecg	O	O
alterations	alterations	O	O
was	was	O	O
observed	observed	O	O
after	after	O	O
pretreatment	pretreatment	O	O
of	of	O	O
the	the	O	O
rats	rats	O	O
with	with	O	O
BN	bn	O	O
52021	52021	O	O
.	.	O	O

Since	since	O	O
the	the	O	O
administration	administration	O	O
of	of	O	O
BN	bn	O	O
52021	52021	O	O
,	,	O	O
at	at	O	O
all	all	O	O
doses	doses	O	O
studied	studied	O	O
,	,	O	O
did	did	O	O
not	not	O	O
alter	alter	O	O
MBP	mbp	O	O
and	and	O	O
HR	hr	O	O
at	at	O	O
the	the	O	O
doses	doses	O	O
used	used	O	O
,	,	O	O
the	the	O	O
bulk	bulk	O	O
of	of	O	O
these	these	O	O
results	results	O	O
clearly	clearly	O	O
demonstrate	demonstrate	O	O
a	a	O	O
protective	protective	O	O
action	action	O	O
of	of	O	O
BN	bn	O	O
52021	52021	O	O
,	,	O	O
a	a	O	O
specific	specific	O	O
antagonist	antagonist	O	O
of	of	O	O
PAF	paf	O	O
,	,	O	O
against	against	O	O
bupivacaine-induced	bupivacaine-induced	O	O
cardiovascular	cardiovascular	O	O
toxicity	toxicity	O	S_disease
.	.	O	O

Thus	thus	O	O
,	,	O	O
consistent	consistent	O	O
with	with	O	O
its	its	O	O
direct	direct	O	O
effect	effect	O	O
on	on	O	O
heart	heart	O	O
,	,	O	O
PAF	paf	O	O
appears	appears	O	O
to	to	O	O
be	be	O	O
implicated	implicated	O	O
in	in	O	O
bupivacaine-induced	bupivacaine-induced	O	O
cardiovascular	cardiovascular	O	O
alterations	alterations	O	O
.	.	O	O

